Wave Life Sciences, Inc. (WVE) Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Wave Life Sciences Ltd. NASDAQ:WVE Healthcare · Biotechnology
Mkt Cap $708.05M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release ⚠ 2
Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update
Wave Life Sciences reported Q3 2026 revenue of $13.2 million (up from $7.6 million a year ago) with a net loss of $61.9 million, or $(0.30) per share.
The company is planning a registrational trial of WVE-006 for AATD with FDA-aligned interim analysis for potential accelerated approval, and dosing is underway in the Phase 2a INLIGHT obesity trial of WVE-007, with a combination trial with weekly tirzepatide and a post-incretin maintenance trial also advancing.
GSK selected a GalNAc-siRNA development candidate using Wave's SpiNA design, earning Wave a $12 million milestone payable in 4Q 2026, with up to $330-$375 million in milestones per program plus royalties still available.
Cash and marketable securities stood at $431.0 million at September 30, 2026, funding operations into 3Q 2028.
• 5d ago AI analysis › Press Release
Wave Life Sciences Third Quarter 2026 Financial Results Scheduled for October 27, 2026
Wave Life Sciences will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, October 27, 2026, to review third quarter 2026 financial results and provide business updates.
This is a scheduling notice only; no results or guidance are included in the release.
Access details are available via the company's investor relations website, with an archived replay to follow.
• 12d ago AI analysis › Press Release
Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026
Wave Life Sciences will host a virtual Research Day on Wednesday, November 4, 2026 at 9:30 a.m. ET.
The company plans to present new data on its RNA medicines platform, covering RNAi, RNA editing, and bifunctional modalities, plus perspectives on the PNPLA3 I148M liver disease opportunity from hepatologist Dr. Arun Sanyal of VCU.
This is a scheduling notice only — no new results are included — but the event itself may carry catalyst value for pipeline programs including obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006), and PNPLA3 (WVE-008).
• 13d ago AI analysis › Press Release
Wave Life Sciences to Present at Chardan’s 10th Annual Healthcare Conference
Wave Life Sciences CEO Paul Bolno will participate in an RNA medicines panel at Chardan's 10th Annual Healthcare Conference in New York on October 20, 2026 at 9:45 a.m. ET.
A live webcast will be available on the company's investor relations site, with an archived replay afterward.
The announcement contains no new clinical or financial data; it is a routine investor-outreach event notice.
• 19d ago AI analysis › Press Release ● Major ⚠ 1
Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD
Wave Life Sciences announced FDA alignment on key aspects of the registrational pathway for WVE-006, its GalNAc RNA-editing oligonucleotide for alpha-1 antitrypsin deficiency.
The planned design is a single two-year registrational trial supporting potential full approval, with a one-year interim analysis that could support accelerated approval based on AATD biomarkers; the FDA also endorsed Wave's LC-MS assay for the program.
WVE-006 remains generally safe and well tolerated in the Phase 1b/2a RestorAATion-2 trial, with 600 mg monthly multidose cohort data expected in Q4 2026 — a near-term catalyst targeting ~200,000 Pi*ZZ patients in the U.S. and Europe.
• 1mo ago AI analysis › Press Release
Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development
GSK selected a hepatology development candidate built on Wave's proprietary SpiNA design GalNAc-siRNA, transitioning it into GSK's pipeline under the companies' research collaboration.
The selection triggers a $12 million milestone payment to Wave, which is also eligible for up to $330-$375 million in development, launch, and commercial milestones per program plus tiered royalties.
Three additional collaboration programs are advancing toward potential candidate selection, supporting the commercial validation of Wave's PRISM platform and RNA-medicines toolkit.
• 1mo ago AI analysis › Press Release ⚠ 2
Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity
Wave Life Sciences initiated a Phase 2a combination trial of WVE-007 (GalNAc-siRNA targeting INHBE) with weekly tirzepatide in adults with obesity (BMI 35-50) and type 2 diabetes.
The placebo-controlled 3:1 trial tests 240 mg and 400 mg doses, with preclinical data showing doubled weight loss versus GLP-1 alone and a differentiated fat-loss-without-muscle-loss profile supporting once- or twice-yearly dosing.
A maintenance trial of WVE-007 to prevent weight regain after incretin cessation remains on track to start in 2H 2026; results inform development across obesity, MASH, type 2 diabetes, and cardiovascular disease.
• 1mo ago AI analysis › Press Release
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer
Wave Life Sciences appointed Dr. Monika Vnuk as Chief Business Officer, a newly created role leading business development, corporate development, and alliance management.
Dr. Vnuk joins from Sanofi, where she was Senior Vice President and Global Head of Partnering and Business Development; she previously spent more than a decade at Pfizer — including leading negotiation of the Pfizer-BioNTech COVID-19 vaccine partnership — and served as Managing Director at Blackstone Life Sciences.
In connection with her appointment, she received an inducement stock option for 375,000 shares at a $4.25 exercise price, granted outside the 2021 Equity Incentive Plan under Nasdaq Listing Rule 5635(c)(4) and vesting over four years with 25% vesting on September 21, 2027.
The hire signals Wave's intent to pursue value-creating transactions as its clinical pipeline — led by obesity candidate WVE-007 and AATD program WVE-006 — advances toward later stages.
• 1mo ago AI analysis › Press Release
Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference
Wave Life Sciences CEO Paul Bolno, MD, MBA, is scheduled to participate in an analyst-led fireside chat at the Cantor 2026 Global Healthcare Conference in New York City on Thursday, September 10, 2026 at 9:45 a.m. ET.
A live webcast will be available via the Investor Events section of the Wave Life Sciences website, with a replay archived for a limited time after the event.
Wave is a clinical-stage RNA medicines company whose pipeline is focused on obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008), alongside clinical programs in Duchenne muscular dystrophy and Huntington's disease.
• 1mo ago AI analysis › Press Release
Wave Life Sciences Announces Completion of Redomiciliation to Delaware
Wave Life Sciences completed its redomiciliation from a Singapore company to a Delaware corporation, effective after the market close on August 7, 2026.
All issued ordinary shares were exchanged on a one-for-one basis for new common stock of the Delaware entity, with the NASDAQ ticker symbol WVE remaining unchanged.
The company stated it does not anticipate any material impact to its employees or day-to-day business operations as a result of the move.
• 2mo ago AI analysis › Press Release
Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware
Wave Life Sciences expects its redomiciliation from Singapore to Delaware to become effective after the close of trading on August 7, 2026.
The transition follows the receipt of requisite shareholder approvals and a July 14 order from the High Court of the Republic of Singapore.
The company plans to file the necessary documentation with the SEC after the market closes on the same day as the effective date.
• 2mo ago AI analysis › Press Release
Wave Life Sciences to Present at Upcoming Investor Conferences
Wave Life Sciences announced that members of its management team will attend the BofA Securities 2026 SMID Cap Executive Insights Event and the Canaccord Genuity 46th Annual Growth Conference in August.
President and CEO Dr. Paul Bolno is scheduled to participate in fireside chats at both events on August 11 and August 12, respectively.
Live webcasts of the presentations will be available on the company's investor relations website, with replays archived for a limited time.
• 2mo ago AI analysis › Press Release ● Major ⚠ 2
Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Wave Life Sciences reported Q2 revenue of $2.3 million, down from $8.7 million in the prior year, with a net loss of $69.4 million compared to a loss of $50.5 million a year ago. The company maintains a strong balance sheet with $490.6 million in cash and equivalents, extending its runway into the third quarter of 2028.
On the clinical front, dosing is underway in the Phase 2a multidose portion of the INLIGHT trial evaluating WVE-007 for obesity. The company expects to initiate Phase 2 trials evaluating WVE-007 in combination with incretins and as a post-incretin maintenance therapy in the second half of 2026.
The company announced that the FDA granted its request for a meeting to discuss a potential accelerated approval pathway for WVE-006 in alpha-1 antitrypsin deficiency (AATD). Additionally, Wave plans to submit a Clinical Trial Application for WVE-008 targeting PNPLA3 liver disease in the second half of 2026.
• 3mo ago AI analysis › Press Release
Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026
Wave Life Sciences announced it will release its second quarter 2026 financial results on July 30, 2026, followed by a conference call at 8:30 a.m. ET.
The company is a clinical-stage biotechnology firm focused on RNA medicines, including programs in obesity and liver disease.
Access to the live webcast will be available via the Investor Events section of the company's website.
• 3mo ago AI analysis › Press Release
Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation
Wave Life Sciences has secured a hearing date of July 14, 2026, before the Singapore High Court to seek approval for its proposed redomiciliation to the United States.
The company has already obtained the requisite shareholder approval for the Scheme of Arrangement, which will transfer the parent company to a Delaware corporation.
Deadlines for filing affidavits and written submissions are set for July 8 and July 10, respectively, with court materials to be made available on the company's Investor Relations website.
• 3mo ago AI analysis › Press Release
Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases
Wave Life Sciences initiated the Phase 2a portion of the INLIGHT trial evaluating WVE-007 in obese individuals with high BMI and comorbidities.
The progression follows Phase 1 data where a single 240 mg dose reduced visceral fat by 14% and total fat by 5% at six months, while preserving muscle mass and being generally well tolerated.
The company plans to begin additional Phase 2 trials in the second half of 2026 to evaluate WVE-007 as an add-on to incretins and as a post-incretin maintenance therapy.
• 4mo ago AI analysis › Press Release
Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1
prnewswire.com • 5mo ago Press Release ● Major
Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing
Wave Life Sciences reported positive Phase 1b/2a data for WVE-006 in alpha-1 antitrypsin deficiency (AATD), showing robust reduction of toxic Z-AAT by 71% and restoration of wild-type M-AAT to 64% of total AAT in the biweekly dosing cohort.
The monthly dosing cohort (400 mg) showed similar efficacy with 68% Z-AAT reduction and 59% M-AAT restoration, supporting a convenient subcutaneous dosing regimen. Editing effects were sustained for at least three months after the last dose.
The data demonstrates restored dynamic AAT production during acute phase responses, a key unmet need in AATD. Wave expects regulatory feedback on a potential accelerated approval pathway from the FDA in mid-2026.
• 5mo ago AI analysis › Press Release
Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
globenewswire.com • 6mo ago Press Release ⚠ 2
Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition
BioMedWire released an editorial analyzing the biotechnology sector's shift toward fair-value accounting, which allows companies to capitalize scientific progress as a balance sheet asset rather than just an expense.
The article highlights Oncotelic Therapeutics as a case study, noting its 45% stake in GMP Bio was recently assessed at over $1 billion in enterprise value.
IO Biotech is mentioned briefly in the list of industry players, with the text noting a strategic shift in 2026 to maximize value for its immune-modulatory cancer vaccines.
• 6mo ago AI analysis › Press Release
Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026
Wave Life Sciences announced that it will host a conference call and webcast on April 28, 2026, to review its first quarter 2026 financial results.
The event is scheduled to begin at 8:30 a.m. ET and will be accessible via the investor relations section of the company's website.
An archived version of the webcast will be made available following the live presentation.
• 6mo ago AI analysis › Press Release
Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States
Wave Life Sciences announced that the Singapore High Court will hear its application to convene a shareholder meeting regarding the proposed redomiciliation from Singapore to the United States on April 29, 2026.
The Scheme of Arrangement under Section 210 of the Companies Act 1967 remains subject to approval by both shareholders and the court to complete the move of the parent company.
The company continues to focus on its RNA medicines platform, with pipeline programs targeting obesity, alpha-1 antitrypsin deficiency, and PNPLA3 liver disease.
• 6mo ago AI analysis › 
